Impact of Early Mobility on Post-Surgery Recovery in Patients Undergoing Oncologic Surgeries

July 20, 2022 updated by: Roswell Park Cancer Institute

Does Increased Mobility Assessed With 3D Motion Tracking Technology Lead to Early Post-Operative Recovery Among Patients Undergoing Oncologic Surgeries

This trial studies the impact of early mobility tracked with a 3-dimensional (3D) motion tracking technology (XSENS) on post-surgery recovery in patients undergoing oncologic surgeries. Xsens uses wireless measurements which could be used in clinical settings to objectively measure movement patterns (the joint range of movement and the distance of movement) during functional activities. Post-surgery mobility tracking may help doctors to identify the minimum required level of mobility after inpatient oncologic surgeries to enhance early post-surgery recovery and decrease early post-surgery complications.

Study Overview

Detailed Description

PRIMARY OBJECTIVES:

I. To investigate objectively using evidence based randomized controlled trial the impact of early mobility (first day after the surgery) after any inpatient oncologic procedures on early recovery of postoperative course.

II. Try to find out the minimum level of postoperative mobility that needed for early postoperative course recovery by objective assessment of range of movement for each participant using 3D motion tracking system (Xsens).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients walk one to two laps around the ward twice per day, and have mobility tracked with Xsens over 5-10 minutes, until discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.

ARM II: Patients walk for minimum 30 minutes per day and mobility is tracked with Xsens over 5-10 minutes up to discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.

After completion of study, patients are followed up for 30 days post discharge.

Study Type

Interventional

Enrollment (Actual)

17

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Buffalo, New York, United States, 14263
        • Roswell Park Cancer Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Ambulant inpatient with a stay of >= 2 days after any inpatient oncologic surgery
  • Eastern Cooperative Oncology Group (ECOG) scale of performance status of less than 3
  • American Society of Anesthesiologist score (ASA) 3 or less
  • Participants who do not engage in regular exercise regimen before the surgery (other than regular occupational physical therapy)
  • Participant or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

  • Patients with altered mental status
  • Patients with psychiatric illness
  • ECOG scale performance status 3 or more
  • ASA score of 4
  • Participants who engage in regular exercise regimen before surgery (at least one session per week)
  • Patients with restricted movement due to other diseases
  • Patients who require continuous monitoring

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm I (usual care)
Patients walk one to two laps around the ward twice per day, and have mobility tracked with Xsens over 5-10 minutes, until discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
Ancillary studies
Receive standard of care
Other Names:
  • standard of care
  • standard therapy
Experimental: Arm II (additional mobility)
Patients walk for minimum 30 minutes per day and mobility is tracked with Xsens over 5-10 minutes up to discharge from hospital. Patients also mobilize (walk out of the bed) on first day post-surgery under supervision and assistant of attending nurse in the floor if the clinical situation allows.
Ancillary studies
Walk for minimum 30 minutes per day

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in Mobility
Time Frame: Baseline up to 30 days post discharge
changes in mobility (as measured by average velocity of pelvis) from baseline to discharge are compared between groups using a one-sided, two-sample t-test.
Baseline up to 30 days post discharge
Early Return of Bowel Motion
Time Frame: Up to 30 days after discharge
Days from operation to passing flatus and/or stool, treated as continuous measure
Up to 30 days after discharge
Presence or Absence of Nausea and/or Vomiting
Time Frame: Up to 30 days after discharge
Presence or absence of nausea and/or vomiting, treated as a binary variable
Up to 30 days after discharge
Presence or Absence of Chest Symptoms
Time Frame: Up to 30 days after discharge
Presence or absence of chest symptoms (cough, sputum, and ability of using incentive spirometry), treated as a binary variable
Up to 30 days after discharge
Early Discharge From the Hospital
Time Frame: Up to 30 days after discharge
Days from operation until hospital discharge, treated as continuous variable
Up to 30 days after discharge
Surgical Related Complications and Readmissions
Time Frame: Up to 30 days after discharge
Presence or absence of surgical complication (including readmission), treated as a binary variable
Up to 30 days after discharge

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Range of Joint Movement in Upper and Lower Joints of Body
Time Frame: Up to 30 days after discharge
Will be measured using the 3 dimensional (3D) motion tracking system (Xsens), to identify the minimum required level of mobility for better early postoperative course recovery.
Up to 30 days after discharge
Post-surgical Complications
Time Frame: Up to 30 days post discharge
The complication status (present/absent) and grades will be summarized by group and compared using Fisher's exact test or the chi-square test, as appropriate.
Up to 30 days post discharge
Change in Exercise Habits Outside of the Hospital
Time Frame: Up to 3 months post discharge
Post study questionnaire .
Up to 3 months post discharge
Application of Sensors in a Hospital Setting
Time Frame: Up to 3 months post discharge
Adequate application of sensors, treated as a categorical variable
Up to 3 months post discharge
Mobility Quality of Life Questionnaire
Time Frame: Up to 3 months post discharge
The correlation between complication status and changes in mobility may be evaluated using a post study questionnaire.
Up to 3 months post discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Khurshid A Guru, Roswell Park Cancer Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 31, 2019

Primary Completion (Actual)

April 10, 2020

Study Completion (Actual)

April 10, 2020

Study Registration Dates

First Submitted

June 20, 2019

First Submitted That Met QC Criteria

June 26, 2019

First Posted (Actual)

June 27, 2019

Study Record Updates

Last Update Posted (Actual)

July 22, 2022

Last Update Submitted That Met QC Criteria

July 20, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • I 80918 (Other Identifier: Roswell Park Cancer Institute)
  • NCI-2019-03139 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Malignant Neoplasm

Clinical Trials on Questionnaire Administration

3
Subscribe